Insider · CIK 0001568850
Lisa M. Giles
Files at MIST (Milestone Pharmaceuticals Inc.), HCWB (HCW Biologics Inc.). First filing -, latest -.
In brief
Lisa M. Giles files SEC Form 4 as director at MIST (Milestone Pharmaceuticals Inc.), and also at HCWB (HCW Biologics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Lisa M. Giles has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Stock Option (right to buy)derivative | +77,000 | $0.00 | $0 | 77,000 | Jun 12, 2026 |
| Jun 10, 2025 | MIST Milestone Pharmaceuticals Inc. | AGrant or award Stock Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 12, 2025 |
| Feb 20, 2024 | HCWB HCW Biologics Inc. | AGrant or award Common Stock | +35,715 | $1.40 | $50k | 35,815 | Feb 22, 2024 |
Questions about Lisa M. Giles
Answered from the filings on this page, as of the latest one.
Is Lisa M. Giles buying or selling?
Lisa M. Giles has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Lisa M. Giles's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lisa M. Giles has 0.
Where does Lisa M. Giles file Form 4?
Lisa M. Giles has filed Form 4 at MIST (Milestone Pharmaceuticals Inc.); HCWB (HCW Biologics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.